Altre lingue Puma Biotechnology, Inc.

Azioni

PBYI

US74587V1070

Tempo reale stimato Cboe BZX Altri mercati azionari 16:13:53 25/04/2024			Variaz. 5gg	Var. 1 gen.
4,75 ^USD	-1,66%		-5,11%	+9,35%

20/03	Puma Biotechnology prevede di avviare uno studio combinato sul cancro al seno nella seconda metà; le azioni salgono	MT
20/03	Puma Biotechnology, Inc. annuncia l'autorizzazione della FDA a procedere con l'IND per Alisertib nel tumore al seno metastatico HER2-negativo e positivo ai recettori ormonali	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results	18/04
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	04/04
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	03/04
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	20/03
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03
Puma Biotechnology : Corporate Presentation	06/03
Puma Biotech: Q4 Earnings Snapshot	29/02
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	29/02
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results	29/02
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	29/02
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	28/02
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference	22/02
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	15/02
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13/02
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13/02
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference	11/01
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	11/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Puma Biotechnology, Inc.

Azioni

PBYI

US74587V1070

Altre lingue

Filtri